Barclays’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-109,656
| Closed | -$4.21M | – | 4791 |
|
|
2023
Q2 | $4.21M | Buy |
109,656
+25,731
| +31% | +$661K | ﹤0.01% | 1446 |
|
|
2023
Q1 | $1.94M | Sell |
83,925
-18,016
| -18% | -$429K | ﹤0.01% | 2221 |
|
|
2022
Q4 | $2.67M | Buy |
101,941
+9,670
| +10% | +$214K | ﹤0.01% | 2048 |
|
|
2022
Q3 | $1.81M | Buy |
92,271
+87,934
| +2,028% | +$1.76M | ﹤0.01% | 1820 |
|
|
2022
Q2 | $75K | Sell |
4,337
-4,053
| -48% | -$63.6K | ﹤0.01% | 3892 |
|
|
2022
Q1 | $137K | Buy |
+8,390
| New | +$114K | ﹤0.01% | 3640 |
|
|
2020
Q4 | – | Sell |
-7,931
| Closed | -$97K | – | 5223 |
|
|
2020
Q3 | $97K | Sell |
7,931
-1,212
| -13% | -$16.2K | ﹤0.01% | 4274 |
|
|
2020
Q2 | $105K | Buy |
9,143
+4,772
| +109% | +$65.8K | ﹤0.01% | 4485 |
|
|
2020
Q1 | $60K | Sell |
4,371
-8,829
| -67% | -$104K | ﹤0.01% | 5116 |
|
|
2019
Q4 | $78K | Buy |
13,200
+6,438
| +95% | +$35K | ﹤0.01% | 5591 |
|
|
2019
Q3 | $36K | Sell |
6,762
-4,791
| -41% | -$31.8K | ﹤0.01% | 6050 |
|
|
2019
Q2 | $89K | Buy |
11,553
+3,973
| +52% | +$60.5K | ﹤0.01% | 5772 |
|
|
2019
Q1 | $151K | Buy |
7,580
+7,084
| +1,428% | +$124K | ﹤0.01% | 5045 |
|
|
2018
Q4 | $7K | Sell |
496
-8,590
| -95% | -$172K | ﹤0.01% | 6350 |
|
|
2018
Q3 | $334K | Buy |
9,086
+3,854
| +74% | +$124K | ﹤0.01% | 4596 |
|
|
2018
Q2 | $182K | Sell |
5,232
-8,545
| -62% | -$328K | ﹤0.01% | 4802 |
|
|
2018
Q1 | $641K | Buy |
13,777
+7,657
| +125% | +$280K | ﹤0.01% | 3710 |
|
|
2017
Q4 | $231K | Sell |
6,120
-5,764
| -49% | -$252K | ﹤0.01% | 4571 |
|
|
2017
Q3 | $634K | Buy |
11,884
+7,560
| +175% | +$449K | ﹤0.01% | 3394 |
|
|
2017
Q2 | $246K | Sell |
4,324
-347
| -7% | -$17.4K | ﹤0.01% | 4193 |
|
|
2017
Q1 | $251K | Buy |
4,671
+2,658
| +132% | +$150K | ﹤0.01% | 4091 |
|
|
2016
Q4 | $115K | Buy |
2,013
+1,155
| +135% | +$69.9K | ﹤0.01% | 4650 |
|
|
2016
Q3 | $54K | Buy |
858
+224
| +35% | +$15.8K | ﹤0.01% | 4933 |
|
|
2016
Q2 | $36K | Buy |
634
+553
| +683% | +$33.6K | ﹤0.01% | 5013 |
|
|
2016
Q1 | $5K | Sell |
81
-157
| -66% | -$12.7K | ﹤0.01% | 5681 |
|
|
2015
Q4 | $33K | Buy |
238
+229
| +2,544% | +$31.1K | ﹤0.01% | 4999 |
|
|
2015
Q3 | $1K | Sell |
9
-23
| -72% | -$2.74K | ﹤0.01% | 6637 |
|
|
2015
Q2 | $5K | Buy |
+32
| New | +$5.28K | ﹤0.01% | 6481 |
|
Barclays's KDNY Position: Q3 2023 in Review
Barclays sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 109,656 shares — an estimated $4.21M sold.
Barclays first reported a position in KDNY in Q2 2015 and held it in 28 quarters. The position peaked at $4.21M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Barclays reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Barclays sold 109,656 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.21M.
- Barclays first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 28 quarters.
- Barclays's Chinook Therapeutics, Inc. Common Stock position peaked at $4.21M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.